In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Open Access
- 26 August 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (11), 2376-2381
- https://doi.org/10.1093/jac/dkq306
Abstract
NXL104 potentiates ceftazidime and ceftaroline against Enterobacteriaceae with extended-spectrum, AmpC, KPC and OXA β-lactamases. We examined whether similar potentiation was obtained against non-fermenters, which are less permeable than Enterobacteriaceae and have more potent efflux. MICs of ceftazidime+NXL104 (with NXL104 at 4 mg/L) and comparators were determined by CLSI agar dilution for: (i) Pseudomonas aeruginosa AmpC mutants and extended-spectrum β-lactamase (ESBL)-producing transconjugants; (ii) clinical P. aeruginosa isolates with AmpC enzymes, ESBLs or up-regulated efflux; (iii) P. aeruginosa and Burkholderia cepacia complex isolates from cystic fibrosis patients; and (iv) Acinetobacter baumannii with OXA carbapenemases, which also compromise ceftazidime. NXL104 reversed AmpC-mediated ceftazidime resistance in P. aeruginosa, reducing MICs for fully derepressed mutants and isolates to ≤8 mg/L. NXL104 also reversed ceftazidime resistance caused by the ESBL PER-1, but not that due to OXA ESBLs or VEB-1 enzyme. Efflux-mediated resistance was unaffected. Resistance to ceftazidime in isolates of P. aeruginosa and the B. cepacia complex from patients with cystic fibrosis was variably overcome, generally to greater effect for B. cepacia. NXL104 had little effect on MICs of ceftazidime for A. baumannii isolates with OXA carbapenemases. The potentiation of ceftazidime against many β-lactamase-producing P. aeruginosa and B. cepacia complex strains confirms that NXL104 penetrates these organisms. The utility of the combination against these pathogens will depend on the local prevalence of strains with β-lactamase- versus efflux-mediated resistance. The lack of potentiation against A. baumannii may reflect failure of NXL104 to penetrate these bacteria to inhibit relevant (OXA-23, -40, -51 and -58) carbapenemases.Keywords
This publication has 22 references indexed in Scilit:
- Efflux Pumps, OprD Porin, AmpC β-Lactamase, and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis PatientsAntimicrobial Agents and Chemotherapy, 2010
- Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolatesInternational Journal of Antimicrobial Agents, 2009
- Emergence of KPC-Producing Pseudomonas aeruginosa in Trinidad and TobagoJournal of Clinical Microbiology, 2009
- In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC CarbapenemasesAntimicrobial Agents and Chemotherapy, 2009
- Crystal Structure of the OXA-48 β-Lactamase Reveals Mechanistic Diversity among Class D CarbapenemasesCell Chemical Biology, 2009
- Revised Approach for Identification of Isolates within the Burkholderia cepacia Complex and Description of Clinical Isolates Not Assigned to Any of the Known GenomovarsJournal of Clinical Microbiology, 2007
- Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast EnglandJournal of Clinical Microbiology, 2006
- PER-1 is still widespread in Turkish hospitals amongPseudomonas aeruginosaandAcinetobacterspp.FEMS Microbiology Letters, 2005
- Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection PotentialAntimicrobial Agents and Chemotherapy, 2004
- Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997–2000)Diagnostic Microbiology and Infectious Disease, 2002